China Oncology ›› 2017, Vol. 27 ›› Issue (7): 559-568.doi: 10.19401/j.cnki.1007-3639.2017.07.007

Previous Articles     Next Articles

A study on the expression of Tim-3 in macrophages and its role in prognosis of non-small cell lung cancer

SHEN Xuejie1,2,3,4, PAN Na1,2,3,4, WEI Feng1,2,3,4, WANG Yang1,2,3,4, ZHENG Yu1,2,3,4, JIN Hao1,2,3,4, CAO Shui1,2,3,4, REN Xiubao1,2,3,4   

  1. 1. National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; 2. Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China; 3. Tianjin Clinical Research Center for Cancer, Tianjin 300060, China; 4. Key Laboratory of Cancer Immunology and Biotherapy, Tianjin 300060, China
  • Online:2017-07-30 Published:2017-08-16
  • Contact: CAO Shui E-mail: caoshui9999@163.com

Abstract: Background and purpose: T cell immunoglobulin and mucin-domain-containing molecules 3 (Tim-3) plays a pivotal role in immune regulation. It participates in the occurrence and development of a variety of diseases, and Tim-3 is associated with immune escape and poor prognosis. The aim of this study was to investigate the expression of negative costimulatory molecule, Tim-3, in macrophages in non-small cell lung cancer (NSCLC) and explore the clinical significance of the expression. Methods: A total of 126 human lung cancer tissue specimens were obtained from pathologically confirmed and newly diagnosed NSCLC patients. The expression level of Tim-3 was analyzed by immunohistochemistry staining. Correlation analysis was performed to study the relationship between Tim-3 expression in macrophages and clinicopathological features. Survival analysis was performed by Kaplan-Meier. Results: Tim-3 was mainly expressed in the cytoplasm and cell membrane of macrophages. Tumor size, lymph node metastasis, TNM stage were significantly correlated with Tim-3 expression level (P=0.002, 0.045 and 0.022, respectively). Tim-3 expression in macrophages was negatively correlated with the prognosis of patients. Higher Tim-3 expression had a shorter overall survival (OS) in patients with stage Ⅲ NSCLC (χ2=12.910, P=0.000; Median OS: 80 months vs 32 months). Moreover, the expression level of Tim-3 had negative correlation with disease-free survival (DFS) in patients with stage Ⅲ NSCLC (χ2=6.135, P=0.013; Median DFS: 41 months vs 24 months). In addition, Tim-3 expression in lymphocytes was negatively correlated with OS and DFS in patients with stage Ⅲ NSCLC (χ2=4.737, P=0.030, Median OS: 80 months vs 47 months; χ2=5.882, P=0.015, Median DFS: 41 months vs 24 months). Conclusion: Tim-3, as a key negative regulator in anti-tumor immunity, contributes to the tumor immune evasion. It has an adverse influence on the prognosis of NSCLC patients.

Key words: T cell immunoglobulin and mucin-domain-containing molecules 3, Non-small cell lung carcinoma, Macrophages, Prognosis